Updated:
Jiangsu Yahong Pharmaceutical Technology Co.
Jiangsu Yahong Pharmaceutical Technology Co. is a Chinese single-family office in Shanghai investing in drug development and biotech ventures.
Jiangsu Yahong Pharmaceutical Technology Co.
Jiangsu Yahong Pharmaceutical Technology Co. functions as a single-family office based in Shanghai, China. Its structure is designed to channel the founding family's pharmaceutical industry wealth into direct life-science investments. The firm's origins remain opaque, but its entity name and registered address in Shanghai suggest a focus on Chinese biotech and drug development. The family office targets early-to-mid-stage therapeutic companies, with a focus on oncology, metabolic disorders, and infectious diseases (per public records). It participates in direct equity investments, joint ventures, and licensing deals. Known co-investors include Chinese contract research organizations and academic spinouts. The firm avoids listed equities and real estate, concentrating entirely on therapeutics. No team size or additional offices are publicly documented. The firm does not maintain a website or LinkedIn presence. As of early 2026, no recent operational events were reported. A structural differentiator is the firm's hybrid identity: a pharmaceutical operating company that also serves as a family investment vehicle. This allows it to negotiate licensing terms as a company while deploying capital as a private investor. Wealth is reinvested into next-generation therapies, not distributed to third parties.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Sector focus
Frequently asked questions
Who runs investment decisions at Jiangsu Yahong Pharmaceutical Technology Co.?
No named principals are publicly disclosed for this entity. The firm is believed to be controlled by the founding family, likely a single principal or small internal team. Investment decisions are likely made by family members or their appointed advisors.
How does Jiangsu Yahong Pharmaceutical Technology Co. source proprietary deal flow?
The firm sources opportunities through direct relationships with Chinese universities, research institutes, and contract research organizations. Its operating company structure may provide preferential access to early-stage therapeutic assets.
What investment stages does Jiangsu Yahong Pharmaceutical Technology Co. typically target?
The firm targets early-to-mid-stage therapeutic companies, specifically preclinical through Phase II clinical trials. It focuses on drug development rather than preclinical discovery or late-stage commercialization.
Which sectors does Jiangsu Yahong Pharmaceutical Technology Co. explicitly avoid?
The firm avoids listed equities, real estate, and non-life-science sectors entirely. Its portfolio is concentrated in oncology, metabolic disorders, and infectious disease therapeutics.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: